News & events

Webinars

Webinars

Previous Webinars

APRIL 21, 2020 05:00PM CEST

The Evolution of Response Evaluation Criteria in Cancer Immunotherapy

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials.

Agenda

o Lesson learnt – the evolution of response criteria in immunotherapy
o Overview of immune modified response criteria
o Challenging cases – pitfall of imaging interpretation

Presenters

• Dr. Yan Liu, CMO, Median Technologies
• Dr. Antoine Iannessi, Medical Director iCRO, Median Technologies

Watch webinar video
February 27, 2018 1:00pm EST

Imaging Phenomics in Precision Medicine

Presented by:  Dr. Loan Hoang-Sayag, Chief Medical Officer and Dr. Peter Bannister, Chief Technology Officer

Recent discoveries in the imaging of various cancers and diseases have shown that imaging features can reflect underlying disease pathophysiology. Imaging features may be apparent at the visual level to a skilled clinician, or may instead only manifest themselves at a much finer scale following image processing that is not routinely applied in the clinic.

Other features may only be identifiable when considering multiple image types in parallel. The quantification of these features, in order to identify fingerprints of a specific disease embedded in medical images, is known as Imaging Phenomics. With the use of deep learning technology and artificial intelligence, a new paradigm of computer-aided medical treatment is emerging and imaging phenomics may serve as another foundation for delivering precision medicine.

What you will learn in this webinar:

  • An introduction to imaging phenomics
  • The types of imaging features that may provide robust and non-invasive indicators of disease state
  • Approaches that can be employed to train and validate prognostic models using deep learning and other artificial intelligence techniques
  • Predictive solutions for cancer and diseases of the liver, prostate and lung
  • Median’s iBiopsy® system for precision medicine
  • A future look at next generation imaging and analysis
Register Here
September 27, 2017 11:00am EST

Metrics that Matter: A Guide to Imaging Measurements in Oncology Clinical Trials

Presented by: Fabien Ricard, MD, Medical Director and Catherine Klifa, PhD, Science Liaison

Medical imaging is an integral component of clinical trials in oncology. For each image type, quantifiable information (biomarkers) can be extracted and analyzed to potentially answer questions about tumor types and stage, and to measure any sign of response to treatment. The most common assessment of response to therapy is to measure anatomical changes to the tumor with treatment. Other quantitative imaging measures derived from functional imaging methods provide equally important physiological information about a tumor, including tumor metabolism, vascularity, and cellularity.

What you will learn in this webinar:
– The difference between qualitative and quantitative biomarkers
– Definition of treatment response criteria
– Various types of measurement: morphological and volumetric
– Functional imaging measurements by modality
– Measurements by cancer/treatment type

April 26, 2017 1pm EST

Going Beyond RECIST – How Volumetric and Functional Analysis Can Add Value to Your Oncology Clinical Trials

Hosted by: Median Technologies

Presented by:  Dr. Robert Ford, Clinical Trials Imaging Consulting, LLC

April 26, 2017 at 1pm EST

Three-dimensional, volume-based measurements address some of the inherent limitations of unidimensional RECIST measurements, provide additional measures of efficacy for modern drug classes, and allow for earlier detection of therapeutic response. Early studies indicate that volume-based measurements are both medically meaningful and add value to a clinical trial. Volume measurements can be easily incorporated into existing clinical trial workflows using segmentation software, that also improves trial efficiency and reproducibility.

What you will learn in this webinar:

The Difference between Routine Versus Advanced Endpoints

More about Volume-Based Endpoints and When to Use Them;

Making Volumetric Tumor Measurements:The Nuts and Bolts

Adding Value to Clinical Trials: Are Volumetric Assessments a True Reflection of Drug Response?

Register today!

Register Here

News and events